Reckitt Benckiser to acquire Adams for $2.3 billion

Share this article:

UK-based cleaning products manufacturer Reckitt Benckiser announced Monday that it has agreed to buy US OTC drug maker Adams Respiratory Therapeutics for $2.3 billion.

Adams is a NASDAQ-listed specialty pharmaceutical group headquartered in Chester, NJ and markets two OTC cough treatments, Mucinex and Delsym, in the US.

Mucinex is currently the No.1 selling OTC expectorant in the US, Adams said.

Adams sales have grown to $332 million in the year to June 2007 compared with $14 million just four years earlier.

Commenting on the acquisition, Bart Becht, CEO of Reckitt Benckiser said in a statement: “Adams will add to our portfolio a new, rapidly growing powerbrand in Mucinex, a market and innovation leader in cough and congestion relief in the USA. Equally important, it will provide Reckitt Benckiser an entry into health care in the USA, the world's largest OTC market.”

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.